DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR IMPLANON
» See Plans and Pricing
All Clinical Trials for Implanon
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00620464 | A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-05-01 | The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON. |
| NCT00725413 | A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2001-11-01 | The primary purpose of this study is to investigate the contraceptive efficacy, safety and acceptability of Organon's subdermal etonogestrel implant in healthy female volunteers in various countries in order to obtain country-specific data. |
| NCT00828542 | Safety of the Etonogestrel-Releasing Implant During the Puerperium of Healthy Women | Completed | University of Sao Paulo | N/A | 2007-07-01 | The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women. |
| NCT00847587 | Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant | Completed | University of Utah | Phase 4 | 2009-01-01 | A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition. |
| NCT00931827 | Acceptability of Long-term Progestin-only Contraception in Europe | Completed | Bayer | N/A | 2008-01-01 | The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Implanon
Condition Name
Clinical Trial Locations for Implanon
Trials by Country
Clinical Trial Progress for Implanon
Clinical Trial Phase
Clinical Trial Sponsors for Implanon
Sponsor Name
